{"commentary":{"count":20,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":8,"x_thread":7,"podcast":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06172127\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DEMETHER","nct_id":"NCT06172127","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=demether-nct06172127. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"DEMETHER","arms":[{"description":"All patients will receive a 6-cycle induction phase with T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on day 1 (D1) of each 21-day cycle (Q3W).\n\nParticipants may continue with PHESGO if T-DXd is discontinued prematurely due to unacceptable toxicity prior to disease progression and following recovering to Grade ≤ 1 toxicity, to Grade 0 in case of ILD/pneumonitis, or to Grade 2 for alopecia/other toxicities not considered a safety risk. If any T-DXd unacceptable toxicity occurs during the first 6 cycles of induction phase with T-DXd, participants may receive taxane-based chemotherapy concomitantly with PHESGO treatment at the discretion of the investigator.\n\nDuring the maintenance phase, all participants will receive PHESGO with a loading dose of 1200 mg pertuzumab/600 mg trastuzumab as a SC injection for 8 minutes on D1 of the first 21-day cycle, and with a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab as a SC Q3W.","label":"T-DXd induction treatment phase followed by PHESGO maintenance treatment phase","type":"EXPERIMENTAL"}],"collaborators":["Hoffmann-La Roche"],"completion_date":{"date":"2029-06","type":"ESTIMATED"},"conditions":["HER2-positive Breast Cancer"],"enrollment":{"count":165,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","type":"DRUG"},{"name":"Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection","type":"DRUG"},{"name":"Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection","type":"DRUG"}],"last_update":"2026-04-29","lead_sponsor":"MedSIR","official_title":"A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtecan as Induction Treatment for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"1-year PFS rate","timeFrame":"Baseline up to 12 months"},{"measure":"3-year OS rate","timeFrame":"Through study completion, an average of 36 months"}],"references":[],"start_date":{"date":"2024-07-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06172127"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/demether-nct06172127"}